Explanatory Note
On September 19, 2022, Catalent, Inc. (“Catalent” and, together with its subsidiaries, the “Company”), issued a press release and filed a Current Report on Form 8-K with the Securities and Exchange Commission (the “Original 8-K”), announcing Catalent’s election of Karen Santiago as Vice President and Chief Accounting Officer. This first amendment to the Original 8-K (“Amendment No. 1”) is being filed to clarify that Ms. Santiago assumed the role of principal accounting officer of the Company on September 19, 2022, upon commencement of her employment with the Company. Concurrent with Ms. Santiago’s assumption of that role, Thomas Castellano, the Company’s Senior Vice President and Chief Financial Officer, relinquished his role as the Company’s principal accounting officer. This Amendment No. 1 also amends the date of report of the Original Form 8-K to September 19, 2022 and clarifies the pro-ration terms of Ms. Santiago’s compensation. This Amendment No. 1 should be read in conjunction with the Original 8-K. Except as set forth herein, no modifications have been made to information contained in the Original 8-K.
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
New Principal Accounting Officer
On September 9, 2022, the board of directors of Catalent, acting by unanimous written consent, elected Karen Santiago as Vice President and Chief Accounting Officer (“CAO”), effective as of the commencement of her employment with the Company, which occurred on September 19, 2022 (the “Effective Date”). As of the Effective Date, she will become a member of the Company’s Executive Leadership Team and assume the role of principal accounting officer of the Company. Concurrent with Ms. Santiago’s assumption of that role, Thomas Castellano, the Company’s Senior Vice President and Chief Financial Officer, relinquished his role as the Company’s principal accounting officer.
Prior to joining Catalent, Ms. Santiago spent 19 years with Bristol-Myers Squibb Company in various roles of increasing responsibility, including Senior Vice President & Corporate Controller, Principal Accounting Officer from 2018 to 2022 and Lead Enabling Functions and Finance Transformation from 2016 to 2018. Since 2013 she has served on the board of The Arc of New Jersey, the state’s largest organization advocating for and serving children and adults with intellectual and developmental disabilities and their families. She holds a Masters in Business Administration and a Bachelor of Science in Accounting from Rutgers University.
There is no arrangement or understanding between Ms. Santiago and any other person pursuant to which she was selected as CAO. There is also no family relationship between Ms. Santiago and any director or executive officer of Catalent, and she has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
The Company has entered into an offer letter, dated August 29, 2022, with Ms. Santiago (the “Offer Letter”), as well as a severance agreement which provides for terms applicable to all senior executives other than Catalent’s Chief Executive Officer and is substantially in the form (the “Form Severance Agreement”) provided as Exhibit 10.3 to the Annual Report on Form 10-K filed September 17, 2010 by Catalent’s wholly owned subsidiary, Catalent Pharma Solutions, Inc. The terms of the Offer Letter and the Form Severance Agreement are summarized as follows:
Base Salary. Ms. Santiago’s annual base salary will be $360,000.
Bonus. Ms. Santiago will be eligible for a cash bonus under the terms of the Company’s Management Incentive Plan, or MIP, the incentive-based annual cash bonus plan for the Company’s executives, with a target amount of $260,000. Ms. Santiago will be eligible for this bonus beginning in our 2023 fiscal year, pro-rated based on her hire date.
Long-Term Incentive Award. Ms. Santiago will be eligible to participate in Catalent’s Long-Term Incentive Plan (the “LTIP”), with an annual grant target of $330,000, beginning with a grant on the Effective Date in respect of Catalent’s 2023 fiscal year, allocated in the same manner as applies to all members of the Company’s Executive Leadership Team, with 30% granted as stock options, 20% as restricted stock units (“RSUs”), and 50% as